SCHEMBL7656289

SCHEMBL7656289

Cc1nc2ccc(C(=O)NN)cc2n1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.69
HDAC1 Q13547 4/20 0.49
HDAC6 Q9UBN7 4/20 0.49
HDAC8 Q9BY41 3/20 0.49
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
THRB P10828 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169108 0.89 PPARG (0.63) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6170044 0.88 PPARG (0.64) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6170948 0.86 PPARG (0.73) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6173254 0.84 PPARG (0.62) PPARGALDH1A1L3MBTL1LMNANPC1
SCHEMBL1160394 0.83 PPARG (0.70) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6170374 0.83 PPARG (0.60) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6134973 0.83 PPARG (0.70) PPARGHDAC1HDAC6HDAC8HDAC3
Hydrochloric Acid SCHEMBL6171221 0.83 PPARG (0.69) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL1160177 0.83 PPARG (0.95) PPARGHDAC1HDAC6HDAC8HDAC3
Atx08-001 SCHEMBL682052 0.82 PPARG (1.00) PPARGHDAC1HDAC6HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed